AMKL
MCID: MGK001
MIFTS: 64

Megakaryocytic Leukemia (AMKL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Megakaryocytic Leukemia

MalaCards integrated aliases for Megakaryocytic Leukemia:

Name: Megakaryocytic Leukemia 12 15 37
Acute Megakaryoblastic Leukemia 12 74 52 58 29 6
Acute Megakaryoblastic Leukaemia 17 32
Acute Megakaryocytic Leukemias 12 71
Acute Megakaryocytic Leukemia 52 58
Acute Myeloid Leukemia M7 52 58
Aml M7 52 58
Amkl 52 58
Acute Megakaryoblastic Leukaemia, Fab M7 12
Acute Megakaryoblastic Leukemia, Fab M7 12
Acute Myeloblastic Leukemia Type 7 52
Leukemia, Megakaryoblastic, Acute 43
Megakaryoblastic Leukemia Acute 54
Leukemia, Myelocytic, Acute 71
Megakaryocytic Myelosis 12
Thrombocytic Leukaemia 12

Characteristics:

Orphanet epidemiological data:

58
acute megakaryoblastic leukemia
Inheritance: Not applicable; Age of onset: Childhood;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8761
ICD9CM 34 207.2
MeSH 43 D007947
NCIt 49 C3170
SNOMED-CT 67 188754005
ICD10 32 C94.2
ICD10 via Orphanet 33 C94.2
UMLS via Orphanet 72 C0023462
Orphanet 58 ORPHA518
UMLS 71 C0023462 C0023467

Summaries for Megakaryocytic Leukemia

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 518 Definition A rare acute myeloid leukemia that occurs predominantly in childhood and particularly in children with Down syndrome (DS-AMKL). Nonspecific symptoms may be irritability, weakness, and dizziness while specific symptoms include pallor, fever, mucocutaneous bleeding, hepatosplenomegaly , neurological manifestations and rarely lymphadenopathy. Acute panmyelosis with myelofibrosis may also be associated with AMKL. In contrast to DS-AMKL (around 80 % survival), non-DS-AMKL is an AML subgroup associated with poor prognosis . Visit the Orphanet disease page for more resources.

MalaCards based summary : Megakaryocytic Leukemia, also known as acute megakaryoblastic leukemia, is related to myeloproliferative syndrome, transient and megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13), and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Megakaryocytic Leukemia is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Idarubicin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Disease Ontology : 12 A leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers.

Wikipedia : 74 Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts... more...

Related Diseases for Megakaryocytic Leukemia

Diseases related to Megakaryocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative syndrome, transient 33.0 TP53 THPO RBM15 JAK3 ITGA2B GATA1
2 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 31.9 RBM15 MRTFA
3 leukemia 31.3 TP53 THPO RUNX1 MRTFA JAK3 JAK2
4 down syndrome 31.2 RUNX1 JAK3 JAK2 GATA1 ETS2 CBS
5 acute erythroid leukemia 31.1 TP53 JAK2
6 acute leukemia 30.8 THPO RUNX1 MPO KITLG JAK2 IL3
7 thrombocytopenic purpura, autoimmune 30.7 THPO ITGA2B IL11
8 childhood leukemia 30.7 TP53 RUNX1 MPO
9 thrombocytopenia 30.6 THPO RUNX1 PTEN PF4 KITLG JAK2
10 gray platelet syndrome 30.6 THPO PF4 ITGA2B GFI1B GATA1
11 myeloid leukemia 30.6 TP53 RUNX1 MPO JAK2 IL3 CSF2
12 hypereosinophilic syndrome 30.6 MPO JAK2 IL3 CSF2
13 deficiency anemia 30.6 THPO JAK2 IL11 GATA1
14 pancytopenia 30.6 TP53 THPO RUNX1 MPO IL3 CSF2
15 monocytic leukemia 30.5 RUNX1 MPO CSF2
16 polycythemia 30.5 THPO KITLG JAK2 IL3
17 myelofibrosis 30.5 TP53 THPO RUNX1 MPO JAK3 JAK2
18 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.4 RUNX1 MPO
19 thrombocytosis 30.4 THPO PF4 KITLG JAK2 IL3 IL11
20 leukemia, acute lymphoblastic 3 30.3 TP53 RUNX1 MPO
21 myeloma, multiple 30.3 TP53 PTEN JAK2 IL3 IL11 CSF2
22 chronic myelomonocytic leukemia 30.2 TP53 RUNX1 MPO JAK2 CSF2
23 hematologic cancer 30.1 TP53 THPO RUNX1 KITLG JAK2 IL3
24 essential thrombocythemia 30.1 TP53 THPO PF4 MPO JAK2 ITGA2B
25 polycythemia vera 30.0 THPO PF4 KITLG JAK3 JAK2 IL3
26 myeloproliferative neoplasm 29.9 THPO RUNX1 PF4 MPO KITLG JAK3
27 acute promyelocytic leukemia 29.9 TP53 THPO RUNX1 PTEN MPO KITLG
28 leukemia, acute myeloid 29.9 TP53 THPO RUNX1 RBM15 PTEN MPO
29 neutropenia 29.8 TP53 THPO MPO KITLG IL3 IL11
30 leukemia, acute lymphoblastic 29.7 TP53 THPO RUNX1 MPO KITLG JAK3
31 myelodysplastic syndrome 29.6 TP53 THPO RUNX1 PTEN MPO KITLG
32 leukemia, chronic myeloid 29.3 TP53 THPO RUNX1 PTEN MPO KITLG
33 neonatal leukemia 10.6 RBM15 MRTFA GATA1
34 retinitis pigmentosa and erythrocytic microcytosis 10.6 JAK2 IL3
35 cyclic neutropenia 10.6 KITLG IL3 CSF2
36 neutropenia, severe congenital, 3, autosomal recessive 10.6 IL3 CSF2
37 mucositis 10.5 IL3 IL11 CSF2
38 acute basophilic leukemia 10.5 MPO GATA1
39 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.5 JAK2 CSF2
40 acquired thrombocytopenia 10.5 THPO ITGA2B IL11
41 granulocytopenia 10.5 MPO IL3 CSF2
42 thrombocytopenia due to platelet alloimmunization 10.5 THPO PF4 ITGA2B
43 chronic leukemia 10.5 PTEN JAK2 GFI1B
44 sodoku disease 10.5 THPO KITLG IL11
45 autosomal dominant macrothrombocytopenia 10.5 ITGA2B GFI1B
46 qualitative platelet defect 10.5 THPO PF4
47 mastocytosis 10.5 KITLG JAK2 IL3
48 amegakaryocytic thrombocytopenia, congenital 10.4 THPO JAK2 IL3 GATA1
49 leukocyte disease 10.4 TP53 JAK2 IL3 CSF2
50 neutrophilia, hereditary 10.4 MPO JAK2 IL3 CSF2

Comorbidity relations with Megakaryocytic Leukemia via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Deficiency Anemia
Neutropenia

Graphical network of the top 20 diseases related to Megakaryocytic Leukemia:



Diseases related to Megakaryocytic Leukemia

Symptoms & Phenotypes for Megakaryocytic Leukemia

UMLS symptoms related to Megakaryocytic Leukemia:


edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CBS GATA1 ITGA2B JAK3 PTEN RUNX1

MGI Mouse Phenotypes related to Megakaryocytic Leukemia:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 CSF2 ETS2 GATA1 GFI1B ITGA2B JAK2
2 cellular MP:0005384 10.32 CSF2 ETS2 GATA1 GFI1B ITGA2B JAK2
3 hematopoietic system MP:0005397 10.28 CSF2 GATA1 GFI1B ITGA2B JAK2 JAK3
4 homeostasis/metabolism MP:0005376 10.24 CSF2 ETS2 GATA1 GFI1B ITGA2B JAK2
5 embryo MP:0005380 10.2 CSF2 ETS2 GATA1 GFI1B ITGA2B JAK2
6 immune system MP:0005387 10.17 CSF2 GATA1 GFI1B ITGA2B JAK2 JAK3
7 endocrine/exocrine gland MP:0005379 10.13 CSF2 ETS2 JAK2 JAK3 KITLG MRTFA
8 mortality/aging MP:0010768 10.03 CSF2 ETS2 GATA1 GFI1B ITGA2B JAK2
9 integument MP:0010771 9.96 CSF2 ETS2 GATA1 GFI1B JAK2 KITLG
10 neoplasm MP:0002006 9.56 CSF2 ETS2 JAK2 KITLG PTEN RBM15
11 skeleton MP:0005390 9.28 CSF2 GATA1 ITGA2B JAK2 KITLG PTEN

Drugs & Therapeutics for Megakaryocytic Leukemia

Drugs for Megakaryocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Idarubicin Approved Phase 3 58957-92-9 42890
2
leucovorin Approved Phase 3 58-05-9 6006 143
3
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
4
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
5
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
9
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
10
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
11
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
12
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
13
Thioguanine Approved Phase 3 154-42-7 2723601
14
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
15
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
16
Mercaptopurine Approved Phase 3 50-44-2 667490
17
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
18
Hydroxyurea Approved Phase 3 127-07-1 3657
19
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
20
Carmustine Approved, Investigational Phase 3 154-93-8 2578
21
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
22
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
23
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
24
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
25
Daunorubicin Approved Phase 3 20830-81-3 30323
26
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
27
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
29
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
30
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
31
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
32
Busulfan Approved, Investigational Phase 3 55-98-1 2478
33
Melphalan Approved Phase 3 148-82-3 460612 4053
34
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
35
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704 32326
36
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
37
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
38
Histamine Approved, Investigational Phase 3 51-45-6 774
39
Cyproheptadine Approved Phase 3 129-03-3 2913
40
Voriconazole Approved Phase 3 137234-62-9 71616
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
42
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
43
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
44 Lintuzumab Investigational Phase 3 166089-32-3
45
tipifarnib Investigational Phase 3 192185-72-1 159324
46 Molgramostim Investigational Phase 3 99283-10-0
47 Immunoglobulins Phase 3
48 Antibodies Phase 3
49 Antibodies, Monoclonal Phase 3
50 Vaccines Phase 3

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
3 Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years Unknown status NCT02140242 Phase 3 study part 1 - dose daunorubicin
4 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
5 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
6 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Unknown status NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
7 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
8 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
9 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
10 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
11 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
12 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
13 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
14 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
15 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl) Completed NCT00962767 Phase 3 gemtuzumab ozogamicin;ATRA plus 6-MP and MTX
17 A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients Completed NCT00044486 Phase 3 Posaconazole oral suspension
18 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
19 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
20 A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus With Tacrolimus/Methotrexate as Graft-versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (BMT CTN #0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
21 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
22 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
23 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
24 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
25 A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Completed NCT00136084 Phase 3 Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
26 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
27 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
28 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
29 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
30 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
31 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
32 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
33 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
34 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
35 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
36 Phase III Study of Safety, Tolerance, Efficacy, Pharmacokinetics, and Costs of Therapy With Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia Terminated NCT00152594 Phase 3 voriconazole
37 A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901) Terminated NCT01339910 Phase 3 Fludarabine and Busulfan;Fludarabine and Melphalan;Busulfan and Fludarabine;Busulfan and Cyclophosphamide;Cyclophosphamide and Total Body Irradiation
38 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
39 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
40 Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia Unknown status NCT00126321 Phase 2 cladribine
41 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
42 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
43 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
44 A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies Unknown status NCT01092026 Phase 1, Phase 2
45 Evaluation of Allogeneic Peripheral Blood Stem Cell Transplants From a Related Donor Without Graft-Versus-Host Prophylaxis in Patients With High Risk of Relapse Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
46 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
47 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
48 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
49 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies Completed NCT00003335 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
50 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate

Search NIH Clinical Center for Megakaryocytic Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Etoposide
etoposide phosphate
Idarubicin
Idarubicin Hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Megakaryocytic Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, megakaryoblastic, acute

Genetic Tests for Megakaryocytic Leukemia

Genetic tests related to Megakaryocytic Leukemia:

# Genetic test Affiliating Genes
1 Acute Megakaryoblastic Leukemia 29

Anatomical Context for Megakaryocytic Leukemia

MalaCards organs/tissues related to Megakaryocytic Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, Lung, Liver, Nk Cells

Publications for Megakaryocytic Leukemia

Articles related to Megakaryocytic Leukemia:

(show top 50) (show all 821)
# Title Authors PMID Year
1
The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. 6 61 54
15070711 2004
2
A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. 54 61
20108342 2010
3
Megakaryocytic blast crisis in a chronic myeloid leukemia patient with a rare variant of Philadelphia rearrangement t(9;22;22) and a constitutional translocation t(3;7). 54 61
20417868 2010
4
NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. 54 61
20149240 2010
5
JAK3: a two-faced player in hematological disorders. 61 54
19747563 2009
6
GATA-2 reinforces megakaryocyte development in the absence of GATA-1. 54 61
19620289 2009
7
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 54 61
19682090 2009
8
Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. 54 61
19633202 2009
9
Vesiculopustular eruption associated with transient myeloproliferative disorder. 54 61
19537279 2009
10
Role for MKL1 in megakaryocytic maturation. 61 54
19136660 2009
11
A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient. 54 61
19119459 2008
12
Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature. 61 54
18372039 2008
13
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. 54 61
18682296 2008
14
JAK and MPL mutations in myeloid malignancies. 61 54
18297515 2008
15
Mining for JAK-STAT mutations in cancer. 54 61
18291658 2008
16
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. 61 54
18094719 2008
17
Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. 61 54
17576817 2007
18
Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. 61 54
17597708 2007
19
JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. 54 61
17252020 2007
20
[The role of GATA1 mutation in acute megakaryocytic leukemia]. 54 61
17176883 2006
21
CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. 54 61
17071479 2006
22
Activating alleles of JAK3 in acute megakaryoblastic leukemia. 54 61
16843266 2006
23
Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. 61 54
16628190 2006
24
Acute megakaryoblastic leukemia and loss of the RUNX1 gene. 61 54
16364766 2006
25
Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. 54 61
16144799 2006
26
GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications. 61 54
15925405 2005
27
GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. 54 61
15916804 2005
28
MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia. 61 54
16111539 2005
29
Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. 61 54
15860665 2005
30
Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. 61 54
15856017 2005
31
GATA transcription factors in hematologic disease. 61 54
16158817 2005
32
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. 54 61
15687366 2005
33
GATA1 in normal and malignant hematopoiesis. 54 61
15659348 2005
34
GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. 61 54
15390312 2005
35
Down syndrome, drug metabolism and chromosome 21. 61 54
15390307 2005
36
Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. 54 61
15307108 2004
37
Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. 54 61
15317736 2004
38
No mutations in the GATA-1 gene detected in patients with acquired essential thrombocythemia. 54 61
15136229 2004
39
Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. 54 61
14684662 2004
40
The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. 61 54
14744791 2004
41
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. 61 54
14512321 2004
42
p-Iodophenol-enhanced luminol chemiluminescent assay applied to discrimination between acute lymphoblastic and minimally differentiated acute myeloid (FAB-M0) or acute megakaryoblastic (FAB-M7) leukemias. 54 61
15570291 2004
43
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. 54 61
14636651 2003
44
AML1 overexpression and/or mutations should be checked in trisomy 21 patients with megakaryocytic leukemia. 61 54
12835737 2003
45
GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. 54 61
12586620 2003
46
Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. 61 54
12393509 2003
47
Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death. 61 54
12019265 2002
48
Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. 54 61
11431691 2001
49
Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. 61 54
11344311 2001
50
Proliferative reaction of myelogenous leukemia cells with cytokines G-CSF, GM-CSF, M-CSF, SCF and TPO. 61 54
9678722 1998

Variations for Megakaryocytic Leukemia

ClinVar genetic disease variations for Megakaryocytic Leukemia:

6 (show all 22) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KMT2A , SEPTIN9 t(11;17)(q23;q25)Translocation Pathogenic 590282 11:118482092-118482093
2 PTEN NM_000314.8(PTEN):c.406T>C (p.Cys136Arg)SNV Pathogenic 183726 rs786201044 10:89692922-89692922 10:87933165-87933165
3 GATA1 NM_002049.3(GATA1):c.154_173dup (p.Ala59fs)duplication Pathogenic 10429 rs398124628 X:48649667-48649668 X:48791260-48791261
4 TP53 NM_001126112.2(TP53):c.636del (p.Arg213fs)deletion Pathogenic 218342 rs864309495 17:7578213-7578213 17:7674895-7674895
5 JAK3 NM_000215.3(JAK3):c.1715C>T (p.Ala572Val)SNV Likely pathogenic 376037 rs121913504 19:17948009-17948009 19:17837200-17837200
6 JAK3 NM_000215.3(JAK3):c.1970G>A (p.Arg657Gln)SNV Likely pathogenic 376113 rs758959409 19:17945969-17945969 19:17835160-17835160
7 JAK3 NM_000215.3(JAK3):c.1503G>T (p.Gln501His)SNV Likely pathogenic 376114 rs201283129 19:17949138-17949138 19:17838329-17838329
8 JAK3 NM_000215.3(JAK3):c.1503G>C (p.Gln501His)SNV Likely pathogenic 376115 rs201283129 19:17949138-17949138 19:17838329-17838329
9 JAK3 NM_000215.3(JAK3):c.260T>C (p.Ile87Thr)SNV Likely pathogenic 376116 rs1057519770 19:17954634-17954634 19:17843825-17843825
10 DICER1 NM_177438.2(DICER1):c.2720T>C (p.Ile907Thr)SNV Conflicting interpretations of pathogenicity 412174 rs200408568 14:95574029-95574029 14:95107692-95107692
11 RASAL3 NM_022904.3(RASAL3):c.-5C>GSNV Uncertain significance 218343 rs76267899 19:15575174-15575174 19:15464363-15464363
12 MT-ND6 NC_012920.1:m.14372C>ASNV Uncertain significance 218344 rs1556424431 MT:14372-14372 MT:14372-14372
13 SLC9A2 NM_003048.6(SLC9A2):c.2173del (p.Gln725fs)deletion Uncertain significance 218345 rs864309496 2:103324677-103324677 2:102708218-102708218
14 ACP3 NM_001099.5(ACP3):c.849_851CAT[1] (p.Ile284del)short repeat Uncertain significance 218346 rs864309497 3:132068830-132068832 3:132349986-132349988
15 MDGA1 NM_153487.4(MDGA1):c.2674T>G (p.Phe892Val)SNV Uncertain significance 218340 rs864309493 6:37606083-37606083 6:37638307-37638307
16 PCF11 NM_015885.4(PCF11):c.3225del (p.Phe1075fs)deletion Uncertain significance 218347 rs864309498 11:82880600-82880600 11:83169558-83169558
17 CORO7 NM_024535.5(CORO7):c.2772+50C>TSNV Uncertain significance 218341 rs1555468179 16:4405237-4405237 16:4355236-4355236
18 MSH2 NM_000251.3(MSH2):c.1511-13_1511-9delinsGTindel Uncertain significance 620635 rs1558510749 2:47693784-47693788 2:47466645-47466649
19 APC NM_000038.6(APC):c.319T>G (p.Ser107Ala)SNV Uncertain significance 620613 rs1485866385 5:112102984-112102984 5:112767287-112767287
20 SHOC2 NM_007373.3(SHOC2):c.1741A>G (p.Met581Val)SNV Uncertain significance 620614 rs1470655019 10:112771568-112771568 10:111011810-111011810
21 JAK3 NM_000215.3(JAK3):c.2164G>A (p.Val722Ile)SNV Benign/Likely benign 134573 rs3213409 19:17945696-17945696 19:17834887-17834887
22 JAK3 NM_000215.3(JAK3):c.394C>A (p.Pro132Thr)SNV Benign/Likely benign 134580 rs3212723 19:17954215-17954215 19:17843406-17843406

Copy number variations for Megakaryocytic Leukemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 158678 21 35304204 35704075 Loss RUNX1 Acute megakaryoblastic leukaemia

Expression for Megakaryocytic Leukemia

Search GEO for disease gene expression data for Megakaryocytic Leukemia.

Pathways for Megakaryocytic Leukemia

Pathways related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 TP53 THPO SRF PTEN PF4 KITLG
2
Show member pathways
13.62 TP53 THPO SRF PF4 JAK3 JAK2
3
Show member pathways
13.48 TP53 THPO KITLG JAK3 JAK2 ITGA2B
4
Show member pathways
13.29 TP53 KITLG JAK3 JAK2 ITGA2B IL3
5
Show member pathways
13.26 TP53 THPO PTEN PF4 KITLG JAK3
6
Show member pathways
13.23 THPO PTEN PF4 KITLG JAK2 IL3
7
Show member pathways
13.21 TP53 THPO PF4 JAK3 JAK2 ITGA2B
8
Show member pathways
13 TP53 THPO PTEN KITLG ITGA2B IL3
9
Show member pathways
12.93 TP53 PTEN KITLG JAK3 JAK2 ITGA2B
10
Show member pathways
12.81 SRF PTEN JAK3 JAK2 ITGA2B IL11
11
Show member pathways
12.81 TP53 RUNX1 PTEN MPO IL3 CSF2
12 12.76 TP53 RUNX1 PTEN KITLG JAK3 JAK2
13
Show member pathways
12.39 THPO JAK3 JAK2 IL3 IL11 CSF2
14
Show member pathways
12.33 TP53 PTEN JAK3 JAK2
15
Show member pathways
12.27 JAK3 JAK2 IL3 ETS2
16 12.27 TP53 SRF PTEN JAK3 ETS2 CSF2
17 12.21 TP53 RUNX1 MPO IL3 CSF2
18
Show member pathways
12.12 PTEN KITLG JAK2 IL3
19
Show member pathways
12.09 JAK3 JAK2 IL3 CSF2
20 11.92 THPO RUNX1 KITLG IL3 IL11 GATA1
21
Show member pathways
11.8 JAK3 JAK2 CSF2
22 11.79 TP53 PTEN ITGA2B
23 11.79 RUNX1 MRTFA MPO KITLG JAK3 JAK2
24 11.76 THPO MPO KITLG ITGA2B IL3 IL11
25 11.73 MPO KITLG GATA1 ETS2
26 11.73 THPO KITLG ITGA2B IL3 IL11 CSF2
27 11.47 KITLG IL3 IL11
28 11.39 SRF PTEN MRTFA
29 11.21 IL3 IL11 CSF2
30 11.11 RUNX1 KITLG ITGA2B IL3 GATA1 CSF2
31 10.94 THPO PF4 KITLG ITGA2B IL3 IL11

GO Terms for Megakaryocytic Leukemia

Cellular components related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 TP53 SRF RUNX1 RBM15 PTEN MRTFA

Biological processes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.02 TP53 PTEN MPO KITLG GATA1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 TP53 SRF RUNX1 PF4 MRTFA IL11
3 negative regulation of cell proliferation GO:0008285 9.97 TP53 SRF PTEN JAK2 GATA1
4 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 SRF RUNX1 MRTFA GATA1 ETS2
5 MAPK cascade GO:0000165 9.83 KITLG JAK3 JAK2 IL3 CSF2
6 positive regulation of cell proliferation GO:0008284 9.8 THPO PTEN KITLG JAK2 IL3 IL11
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 JAK2 IL3 CSF2
8 erythrocyte differentiation GO:0030218 9.67 JAK3 JAK2 GATA1
9 hematopoietic stem cell differentiation GO:0060218 9.64 TP53 SRF
10 dendritic cell differentiation GO:0097028 9.63 GATA1 CSF2
11 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.63 JAK3 JAK2
12 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.63 PF4 GATA1 CSF2
13 positive regulation of leukocyte migration GO:0002687 9.62 KITLG ITGA2B
14 regulation of myeloid cell differentiation GO:0045637 9.61 RUNX1 CSF2
15 primitive streak formation GO:0090009 9.61 SRF ETS2
16 regulation of JAK-STAT cascade GO:0046425 9.6 JAK3 JAK2
17 tyrosine phosphorylation of STAT protein GO:0007260 9.58 JAK3 JAK2
18 enzyme linked receptor protein signaling pathway GO:0007167 9.57 JAK3 JAK2
19 regulation of cytokine-mediated signaling pathway GO:0001959 9.56 RUNX1 IL3
20 megakaryocyte differentiation GO:0030219 9.55 IL11 GATA1
21 regulation of megakaryocyte differentiation GO:0045652 9.55 RUNX1 RBM15 PF4 ITGA2B GATA1
22 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.54 THPO KITLG
23 myeloid cell differentiation GO:0030099 9.54 THPO GATA1 CSF2
24 thrombopoietin-mediated signaling pathway GO:0038163 9.52 THPO RBM15
25 positive regulation of transcription via serum response element binding GO:0010735 9.51 SRF MRTFA
26 embryonic hemopoiesis GO:0035162 9.5 KITLG IL3 GATA1
27 cytokine-mediated signaling pathway GO:0019221 9.5 TP53 PF4 JAK3 JAK2 IL3 IL11
28 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.1 TP53 KITLG JAK2 IL3 IL11 GATA1

Molecular functions related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 TP53 SRF RUNX1 RBM15 PTEN PF4
2 growth factor activity GO:0008083 9.35 THPO KITLG IL3 IL11 CSF2
3 RNA polymerase II transcription factor binding GO:0001085 9.33 TP53 GFI1B GATA1
4 cytokine activity GO:0005125 9.1 THPO PF4 KITLG IL3 IL11 CSF2

Sources for Megakaryocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17